IgD antibody (AA 111-160)

Catalog No. ABIN7229068

This anti-IgD antibody is a Rabbit Polyclonal antibody detecting IgD in ELISA and IHC (p). Suitable for Human.

Quick Overview for IgD antibody (AA 111-160) (ABIN7229068)

Target: IgD

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This IgD antibody is un-conjugated

Application: ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-IgD Antibody

Binding Specificity: AA 111-160

Purpose: IgD Polyclonal Antibody

Specificity: The antibody detects endogenous levels of IgD

Purification: The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen

Immunogen: Synthesized peptide derived from part region of human IgD protein at AA range: 111-160

Isotype: IgG

Application Details

Application Notes: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC-P (1:50-1:200), ELISA (1:10000-1:20000).

Comment:

Primary Antibody

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, containing 0.02 % Sodium Azide as preservative and 50 % Glycerol as stabilizer.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Target Details for IgD

Target: IgD

Target Type: Antibody

Background: Rabbit Anti-IgD Polyclonal Antibody,Ig delta chain C region,Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen.,IgD

UniProt: P01880